Novartis AG (NVSEF)
| Market Cap | 220.46B |
| Revenue (ttm) | 49.94B |
| Net Income (ttm) | 17.60B |
| Shares Out | n/a |
| EPS (ttm) | 8.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 5.23 (4.75%) |
| Ex-Dividend Date | Oct 4, 2023 |
| Volume | 30 |
| Open | 117.28 |
| Previous Close | 117.28 |
| Day's Range | 108.18 - 117.28 |
| 52-Week Range | 90.24 - 123.55 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsNews
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirs...
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.
Novartis Posts Results Above Estimates, Raises Outlook
Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.
Novartis Lifts Guidance Again After Key Drugs Help Results
The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts' expectations, boosted by revenue from its key drugs.
Novartis hikes FY forecast after Q3 profit beat
Novartis posts Q3 earnings with 10 per cent sales growth and 20 per cent core income growth. The drug maker has also hiked its FY guidance.
Novartis: we are exploring obesity drugs but other areas provide growth for years
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provi...
Novartis lifts 2024 guidance for 3rd time on wider use of its drugs
Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (...
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
:max_bytes(150000):strip_icc():format(jpeg)/biotech_research_shutterstock_539866399-1815ece1983542b498a6b74bb3673015.jpg)
This Biotech Stock Has Doubled Its Value TodayHere's Why
Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion.
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.
Novartis AG (NVS) Renal Portfolio Update Call Transcript
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) rose sharply during Monday's session after the company ...
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech fir...
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) stock is trading higher on Monday after the company announced a global exclusive development and commercialization license agreement with Novartis AG (NYSE:...
Monte Rosa jumps on $150M license deal with Novartis
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 glomerulopat...
What To Expect When Novartis Reports Q3 2024 Results
Novartis is poised to exceed expectations in Q3 with strong revenue growth from key products, despite negative updates on Entresto litigation.
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines fo...
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Basel, October 24, 2024 – This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer were updated to recommend ribociclib (Kisqali®) as a Category 1 preferred C...
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
On Friday, Novartis AG (NYSE: NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Kisqali (ribociclib) ....
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe...
Novartis receives positive CHMP opinion for its breast cancer treatment
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...